NASDAQ:GOVX

GeoVax Labs Q2 2026 Earnings Results & Report

GeoVax Labs logo
$2.02 +0.32 (+18.48%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$1.92 -0.10 (-4.70%)
As of 11/16/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GeoVax Labs beat analyst earnings expectations in its Q2 2026 results, released July 27, 2026. The company reported EPS of -$23.28 versus the -$51.84 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
Before Market Opens
Conference Call
4:00 PM ET

GeoVax Labs EPS Results

Actual EPS
-$23.28
Consensus EPS
-$51.84
Beat/Miss
Beat by +$28.56
One Year Ago EPS
N/A

GeoVax Labs Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

GeoVax Labs Q2 2026 Earnings FAQ

GeoVax Labs (NASDAQ:GOVX) reported earnings of -$23.28 per share for Q2 2026, beating the consensus estimate of -$51.84. The report was announced on Monday, July 27, 2026.

GeoVax Labs Earnings Headlines

GeoVax Labs (GOVX) Expected to Post Earnings on Thursday
I'm handing you this stock today
Elon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.tc pixel
GeoVax Enters Into $1 Million Revolving Loan Agreement
GeoVax Enters Into $1 Million Revolving Loan Agreement
See More GeoVax Labs Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GeoVax Labs? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GeoVax Labs and other key companies, straight to your email.

About GeoVax Labs

GeoVax Labs (NASDAQ:GOVX) is a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer. The company’s research is based in part on modified vaccinia Ankara (MVA), a viral-vector platform designed to prompt immune responses, including through the presentation of virus-like particles.

Its vaccine pipeline includes GEO-CM04S1, an investigational COVID-19 vaccine being studied in clinical trials, as well as programs targeting other infectious diseases. GeoVax also develops Gedeptin, an investigational cancer therapy designed to make tumor cells more susceptible to treatment.

GeoVax is based in the United States and focuses on research and clinical development; its candidates are investigational and have not been established here as approved products.

View GeoVax Labs Profile